In our in vivo studies, loop2&3 inhibition by therapeutic sclerostin antibody attenuated the suppressive effects of sclerostin on inflammatory cytokines and chemokines expression, AA and atherosclerosis progression in hSOSTki.Col1a2+/G610C.ApoE-/- mice with AngII infusion. Here, SOST is linked to atherosclerosis.